Taking daily aspirin does not lower the risk of dying, developing dementia, or becoming physically disabled in healthy older adults, even though these were the main goals of the study.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of RCTs would definitively determine whether low-dose aspirin reduces all-cause mortality, dementia, or physical disability in healthy elderly populations across multiple trials.
A systematic review and meta-analysis of all randomized controlled trials comparing daily low-dose aspirin (75–100 mg) to placebo in adults aged 65 or older without cardiovascular disease, with individual outcomes of all-cause mortality, incident dementia (diagnosed by standardized criteria), and persistent physical disability (Katz ADL ≥4) as primary endpoints, using individual participant data and adjusting for age, sex, and baseline risk.
A new RCT with pre-specified, adjusted analyses of individual components could definitively determine whether aspirin affects mortality, dementia, or disability independently.
A double-blind, placebo-controlled RCT of 20,000 healthy adults aged 70–80, randomized to 100 mg aspirin or placebo daily, with pre-specified primary endpoints of all-cause mortality, incident dementia (using DSM-5 criteria), and persistent physical disability (Katz ADL ≥4 for ≥6 months), with statistical adjustment for multiple comparisons using Bonferroni correction and 7-year follow-up.
A prospective cohort could estimate whether aspirin use is associated with lower rates of dementia or disability over time in real-world elderly populations.
A prospective cohort study following 30,000 adults aged 70+ in primary care systems for 10 years, tracking aspirin use (dose, duration), incident dementia (via clinical diagnosis and cognitive testing), and persistent disability (via annual ADL assessments), adjusting for vascular risk factors, medication use, and socioeconomic status.
A case-control study could assess whether prior aspirin use is associated with reduced incidence of dementia or disability in elderly individuals who later developed these conditions.
A case-control study comparing 1,200 elderly individuals diagnosed with dementia or persistent physical disability after age 70 to 1,200 matched controls without these conditions, using pharmacy records and structured interviews to assess aspirin use in the 5–10 years prior to diagnosis, adjusting for age, sex, and comorbidities.
A cross-sectional survey could estimate the prevalence of dementia or disability among elderly aspirin users at a single point in time.
A cross-sectional survey of 8,000 adults aged 70+ in community settings, assessing current aspirin use and current cognitive status (MMSE) and functional status (Katz ADL), with adjustment for age, sex, and education.